Novo Nordisk said on Thursday it would buy U.S.-based Akero Therapeutics for up to $5.2 billion to add its promising experimental liver disease drug, in the first major deal by the Danish drugmaker's ...

Novo Nordisk said on Thursday it would buy U.S.-based Akero Therapeutics for up to $5.2 billion to gain access to a promising liver disease drug candidate, in the first major deal by the Danish ...

Novo Nordisk A/S agreed to buy Akero Therapeutics Inc. for as much as $5.2 billion to expand its portfolio in a type of liver disease that’s linked to obesity.

The deal is the third acquisition since May involving a drug that could reverse liver scarring in people with metabolic dysfunction-associated steatohepatitis.

Novo Nordisk, the Danish drugmaker behind Ozempic and other weight-loss drugs, said it’s paying up to $5.2 billion to buy ...

Akero shareholders will receive $54 per share initially, plus $6 per share contingent on U.S. regulatory approval of its EFX drug by June 30, 2031.

Denmark’s Novo Nordisk said on Thursday that it has agreed to buy Akero Therapeutics - a clinical-stage company developing ...

Novo Nordisk is acquiring Akero Therapeutics for drug candidate efruxifermin, which executive say could be first and best in ...

Novo Nordisk has struck a deal to buy Akero Therapeutics for up to $5.2 billion, teeing up a showdown with Roche and others in a blockbuster liver disease market. Akero confirmed its status as a key ...

Akero Therapeutics stock surged nearly 20% today. Novo Nordisk announced it will acquire Akero for $4.7 billion in cash. The deal values Akero shares at $54 each, plus up to $6 more if FDA approves ...

A view shows the logo of Novo Nordisk at the company's office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024. REUTERS/Tom Little STOCKHOLM (Reuters) -Novo Nordisk said on ...